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Abstract
The absence of biological markers allowing for the assessment of the evolution and prognosis of glioblastoma (GBM) is a
major impediment to the clinical management of GBM patients. The observed variability in patients’ treatment responses
and in outcomes implies biological heterogeneity and the existence of unidentified patient categories. Here, we define
for the first time three GBM patient categories with distinct and clinically predictive three-dimensional nuclear-telomeric
architecture defined by telomere number, size, and frequency of telomeric aggregates. GBM patient samples were ex-
amined by three-dimensional fluorescent in situ hybridization of telomeres using two independent three-dimensional
telomere-measurement tools (TeloView program [P1] and SpotScan system [P2]). These measurements identified three
patients categories (categories 1-3), displaying significant differences in telomere numbers/nucleus (P1 = .0275; P2 ≤
.0001), telomere length (P1 and P2 = .0275), and number of telomeric aggregates (P1 = .0464; P2 ≤ .0001). These cat-
egories corresponded to patients with long-term, intermediate, and short-term survival, respectively (P = .0393). The
time to progression analyses showed significant differences between the three categories (P = .0167). There was a
correlation between time to progression, median survival, and nuclear telomere architecture. Our study suggests a link
between patient outcome and three-dimensional nuclear-telomere organization and highlights the potential clinical
power of telomere signatures as a new prognostic, predictive, and potentially pharmacodynamic biomarker in GBM.
Furthermore, novel automated three-dimensional high-throughput scanning as developed here permits to obtain data
from 300 nuclei in 20 minutes. This method is applicable to any cell type and scanning application.
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Introduction
Glioblastoma (GBM) is the most common and aggressive primary ma-
lignant astrocytic brain tumor in adults [1]. Despite decades of experi-
mentation with a view to improving outcomes for patients with this
disease, GBM remains fatal, with a median survival (MS) of approxi-
mately 12 to 15 months [2]. GBM is associated with one of the worst
5-year survival rates among all human cancers [3]. Interestingly, how-
ever, patients with one type of GBM, dubbed “GBM with long-term
survival,” survive for more than 36 months, a fact that highlights the
biologic heterogeneity of this disease [3].
Recent molecular studies have enhanced our understanding of the
molecular pathogenesis of GBM.GBMsmay develop as primary or type
1 GBM, with epidermal growth factor receptor amplification, or evolve
from a low-grade diffuse astrocytoma after TP53 mutation, eventually
leading to secondary or type 2 GBM [1,4,5]. However, 30% of GBM
showmolecular alterations that correspond to neither the type 1 nor the
type 2 pathway [6–8], pointing to the limitations of this approach to
molecular stratification. More so, this molecular stratification does not
impact the choice of therapy or patient’s outcome.
So far, the most useful prognostic tools in this disease remain clinical
indices such as age, the Karnofsky Performance Status (KPS) score and
the histopathologic grade, as was reported in the recursive partitioning
analysis performed by the RTOG (Radiation Therapy Oncology
Group) [9], as well as the Ki-67 proliferative index. Recently, attempts
to categorize GBM according to the response to chemotherapy were
proposed. Inactivity of the O6-methylguanine-DNA methyltransferase
seems to increase the responsiveness of GBMs to alkylating agents.
However, the O6-methylguanine-DNA methyltransferase promoter is
methylated in only 45% of GBM [10,11]. Various molecules have been
proposed as potential biomarkers, but none has met with clinical accep-
tance yet [12].
The three-dimensional organization of the genome and the nucleus
is an essential component of tumorigenesis as stipulated by Theodore
Boveri (1862-1915) a century ago [13,14]. Telomeres, the nucleopro-
tein complexes located at the end of eukaryotic chromosomes, have
essential roles in preserving chromosomal integrity. Intact telomeres
prevent end-to-end fusions, degradation of the chromosome ends, and
contribute to the adequate chromosome positioning within the nucleus
[15]. The telomeres consist of a tandem repeated DNA sequence
(TTAGGG in vertebrates) that varies in length from 5 to 15 kb in
humans. Telomere dysfunction is known to promote chromosomal
instability (CIN) and carcinogenesis [16]. In most human somatic
cells, telomeres act as a mitotic clock that limits indefinite cell division
[17]. Telomeres are organized in a very typical way within the three-di-
mensional space of the nucleus, and telomeres of normal cells do not
overlap [18] and are localized in microterritories [19]. In contrast, telo-
meres of tumor cell nuclei show an altered three-dimensional nuclear
organization and form telomeric aggregates (TAs) that can be observed
in the interphase nucleus [18]. Alterations in the nuclear telomere
architecture and telomeric dysfunction are associated with CIN (struc-
tural and numerical CIN) [20,21], which is a hallmark of GBM
[6,22]. In the context of this study, we examined whether the telomeric
nuclear architecture in GBM could serve as a marker of genetic insta-
bility and a biological marker, predicting patient outcome.
In the present article, we introduce the three-dimensional telomeric
signatures of GBM nuclei and propose the use of these signatures as
a novel all-encompassing biomarker suitable for characterizing and
stratifying GBM and allowing us to predict patient survival with in-
creased accuracy. In addition, the novel high-throughput automated
three-dimensional telomeric scanning approach that we developed
and applied in a blinded study to the GBM patients permits a quick
scan and analysis of hundreds of nuclei for this and any related clinical
or basic research application.
Materials and Methods
Patients
This study received approval by the research ethics board on human
studies at the Centre Hospitalier Universitaire de Sherbrooke. Patients
undergoing or having undergone surgery for GBM at the Centre Hos-
pitalier Universitaire de Sherbrooke were enrolled in this study after
the obtaining of written informed consent. The patient population
included in this study was composed of 11 individuals, 8 (72.7%)
men and 3 (27.3%) women ranging in age from 24 to 66 years, with
a median age of 46.5 years. These patients all depicted a preoperative
presumptive diagnosis of GBM that was confirmed at surgery. The fresh
surgical biopsies obtained immediately after resection in the operating
room were collected prospectively. All surgeries were performed on
newly diagnosed, treatment-naive patients. Immediately after collec-
tion, touch preparation smear slides (TP slides) were prepared. The
TP slides were performed by smearing a core biopsy onto a glass slide,
which was then air-dried [23]. The TP slides were fixed using fresh
Carnoy (3 vol. methanol/1 vol. glacial acetic acid), air-dried overnight
in a chemical hood, and stored at −20°C until they were used for quan-
titative fluorescent in situ hybridization (FISH).
Histopathologic Analysis
Tumors were classified according to the World Health Organiza-
tion (WHO) classification [1]. After surgical removal, tumor samples
were fixed in 10% formaldehyde and embedded in paraffin. Three-
micrometer sections were stained with hematoxylin and eosin and
submitted to immunohistochemical reactions for the detection of glial
fibrillary acidic protein (GFAP), TP53, and epidermal growth factor re-
ceptor expression. Additional sections were submitted for K-67 antibody
staining to evaluate the proliferative index, which was defined as the ratio
between the number of Ki-67–positive tumor cell nuclei and the total
number of tumor cell nuclei counted; areas of high positivity were se-
lected for the counts. Tumor vascularization was evaluated with the
CD34 antibody. All antibodies were provided by DAKO (Carpinteria,
CA). Tumors exhibiting variable GFAP-positive cells within a fibril-
lar matrix showing high cellularity, nuclear pleomorphism, and neo-
angiogenesis and displaying necrotic areas together with a high mitotic
count and/or Ki-67 proliferative index were classified as GBM.
Fluorescent In Situ Hybridization Protocol for
Three-dimensional Analysis
The TP slides were thawed for 1 hour at room temperature (RT).
The procedure was performed as described previously [20]. Briefly,
slides were incubated in 3.7% formadehyde/phosphate-buffered
saline (PBS; pH 7.4) for 20 minutes and washed three times in 1×
PBS for 5 minutes each. Slides were incubated in 0.5% Triton X-100
for 3 minutes followed by an incubation in 20% glycerol for 1 hour,
and three-dimensionally preserved by four repeated cycles of glycerol/
liquid nitrogen treatment [24] and washed twice in 1× PBS for 5 min-
utes each followed by a 5-minute incubation in 0.1N HCl. Before
fixation in 3.7% formamide/2× SSC at pH 7.0 for 1 hour, slides were
washed twice for 5 minutes in PBS. Immediately after fixation, 8 μl of
PNA telomeric probe (Dako, Glostrup, Denmark) was added to the
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slide. For denaturation of the nuclear DNA and the probe, the slides
were incubated at 80°C for 3 minutes followed by hybridization at
30°C for 2 hours using aHybrite (Vysis; AbbottDiagnostics, Des Plains,
IL). The slides were washed twice for 15 minutes in 70% formamide/
10 mMTris pH 7.4 followed by washing in 1× PBS at RT for 1 minute
while shaking and in 0.1× SSC at 55°C for 5 minutes while shaking.
Slides were washed in 2× SSC/0.05% Tween 20 twice for 5 minutes
each at RTwhile shaking for 5 minutes, after which they were counter-
stained with 4′,6-diamino-2-phenylindole (DAPI) (0.1 μl/ml). Excess
DAPI was removed with deionized distilled water before dehydration
in ethanol at 70%, 90%, and 100% for 2 minutes each. The slides were
then air-dried and cover slipped with Vestashield (Vector Laboratories,
Burlington, Ontario, Canada) for analysis.
Image Acquisition and Three-dimensional Image Analysis
Using TeloView System
Imaging data from all patient GBM tissues were obtained by two in-
dependent image acquisition methods. As a criterion standard, we per-
formed three-dimensional image analysis on 30 interphase nuclei per
slide using an AxioImager Z1 microscope (Carl Zeiss Canada Ltd,
Toronto, Canada) and an AxioCam HRm charge-coupled device (Carl
Zeiss CanadaLtd, Toronto, Canada) [20]. A 100× oil objective lens (Carl
Zeiss Canada Ltd, Toronto, Canada) was used at acquisition times of
366 milliseconds for Cy3 (telomeres) and 109 milliseconds for DAPI
(nuclei). Sixty z-stacks were acquired at a sampling distance of xy:
107 nm and z: 200 nm for each slice of the stack. AxioVision 4.6 software
(Carl Zeiss Canada Ltd, Toronto, Canada) and a constrained iterative
algorithm [25] were used for deconvolution. Deconvolved images were
converted into TIFF files and exported for three-dimensional analysis
using the TeloView software program [20].
Image Acquisition and Three-dimensional Image Analysis
Using the Novel SpotScan System
The slides subjected to TeloView analysis were also scanned and ana-
lyzed using a novel SpotScan system (Applied Spectral Imaging,
Migdal HaEmek, Israel) and the newly developed three-dimensional
TeloScan software. The system uses a fully automated Olympus BX61
microscope (Olympus, Center Valley, PA) equipped with filters for
DAPI and tetramethyl rhodamine iso-thiocyanate (TRITC); the soft-
ware included CaseDataManager 6.0 and ScanView (Applied Spectral
Imaging, Migdal Ha-Emek, Israel). Imaging was done with a ×60 mag-
nification oil objective. Cells were detected based onDAPI nuclear stain.
For each cell, images of 10 focal planes 0.7 μm apart were collected.
SpotScan analyzed the three-dimensional data based on DAPI (nucleus)
and TRITC (telomeres). The data collected from each scan included
information on number of signals, signal intensity, and the existence
of aggregates within each nucleus examined. Three hundred nuclei
per 20minutes per scanned slide were classified according to their num-
ber of telomeres and recorded. Data were saved in Excel format. This
tool combined with three-dimensional quantitative FISH technique
and the data analyses will categorize a GBM patient in 9 to 12 hours
after getting the sample.
Data Presentation and Statistical Analysis
Three types of histogram were produced: 1) line graphs showing the
distribution in the intensity of the registered telomeric fluorescent sig-
nals, 2) histograms of the distribution of the number of aggregates per
cell, and 3) histograms of the distribution of the number of registered
signals per cell. The percentage of cells having TAs, the mean number
of signals, and the mean number of aggregates per cell were calculated.
The histogram data from different samples were combined into a single
chart for comparison.
Overall Survival and Time to Progression
Kaplan-Meier curves were estimated for survival and time to pro-
gression (TTP). Survival curves were compared with the log-rank tests.
Distribution of telomere intensities was compared by χ 2 analysis,
whereas summary of cell parameters was analyzed with nested factorial
analysis of variance. Significance level was set at α = 0.05.
Results
Clinical Surrogates and Pathological Diagnosis
Data were collected from a total of 11 nonconsecutive patients oper-
ated on between 2004 and 2009. Patients were selected for this analysis
based on the disparity in their clinical evolution, so as to create a hetero-
geneous clinical group. The conditions of all of these 11 patients were
initially diagnosed as GBM tumor (Table 1) according to the WHO
criteria [1]. These patients presented with variable clinical findings.
Most of the patients presented with focal neurological symptoms related
to the tumors.
Number of Telomeres, Nuclear Distribution of Telomeres,
and TAs
We first analyzed the total number of telomeres in each sample with
two methods (TeloView and TeloScan) and thereafter observed three
categories of patients (Figures 1, 2, and 3). Figure 1 illustrates telomeric
nuclear signals of each patient category in two-dimensional and three-
dimensional images as determined using imaging and three-dimensional
reconstruction after constrained iterative deconvolution (Materials and
Methods) [20,25]. Figure 2 sums up the data of 30 nuclei per category
as identified in our blinded study after the use of the quantitative three-
dimensional telomere analysis program TeloView [26]. Figure 3 shows
screenshots of image galleries and patient histograms that were obtained
after three-dimensional automated scanning of nuclear telomeric signals
(see Materials and Methods).
Patients were grouped into three categories that can be summarized
by differences in telomere signal intensities and numbers as revealed
by TeloView analysis (Figure 2) and TeloScan (Figure 3). TeloView in-
dicated the presence of three different telomeric profiles that are shown
in Figure 2, A, B, and C , respectively. These profiles became appar-
ent after the quantitative analysis of 30 nuclei of touch preparations
prepared at surgery from treatment-naive patients. In addition, these
profiles indicate some diversity within the tumor cell nucleus population.
For example, Figure 2, A and B, indicates that there are three sub-
populations: nuclei with low relative fluorescent intensities representing
cells with short telomeres, nuclei with intermediate relative fluorescent
intensity indicating intermediate length of telomeres, and nuclei with
telomeric signals of high intensity, that is, large telomeres. Figure 2C
illustrates that this latter patient group lacks cells with very short telo-
meres, that is, signals with low fluorescent intensity.
In general, interphase nuclei display less telomeres than expected due
to their organization inmicroterritories and/or aggregates [19,27]. Telo-
mere numbers in our patients vary as obvious when profiles of Figure 2,
A, B, andC , are compared (see arrows). Figure 2A indicates that patients
within this category have a maximum number of 40 detected telomeric
signals, Figure 2B indicates that that group has less telomeric signals
(maximum is 20/cell), whereas Figure 2C shows that this patient group
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has increased numbers of telomeres (>50 per cell) when compared with
the other two groups.
Automated three-dimensional scanning using TeloScan (Figure 3)
performed on the identical samples examined, scanned and classified
300 cells per patient and also identified three patient categories. The
first category (Figure 3A) shows telomere numbers ranging from 5 to
50, with most telomeres being in the small to intermediate telomere
number groups. The second category of scanned profiles (Figure 3B)
has telomere numbers that vary from 5 to 100, with most cells being
in the mid size range. The third category of scanned profiles (Fig-
ure 3C ) also displays 5 to 100 telomeres per nucleus; however, most
of the signals are in the high number range (50-100 telomeres).
In conclusion, both assays led to the identical categorization of
patients, although TeloScan (Figure 3) examine higher numbers of cells
than TeloView.
After the analysis, the samples were decoded. The first category
of patients was composed of two patients (P6 and P7), the second
category was composed of six patients (P2, P3, P4, P9, P10, and
P11), whereas the third was composed of three patients (P1, P5, and
P8; Table 1). These categories displayed significant differences along
three parameters: telomere numbers/nucleus (P = .0275 with TeloView
data and P ≤ .0001 with TeloScan data), telomere length (P = .0275
with TeloView and TeloScan data), and number of TAs (P = .0464
with TeloView data and P ≤ .0001 with TeloScan data).
With respect to TAs, category 1 displayed the lowest level, whereas
category 2 was intermediate, and category 3 presented the highest TAs
level. We did not find significant differences when analyzing the aver-
age telomeric intensities (P = .3132) and the total telomeric intensities
(P = .3147) between the three categories of patients.
Telomeres versus TTP and MS
The MS for the 11 patients was 551 days (calculated from day of
diagnosis to day of death or censoring), and the mean survival was
515 days (SE = ±75). As shown in Figure 4, patients in category 1
(curves CI) are characterized by longest TTP (591 days) and longest
MS on Kaplan-Meier estimates (one censored; one died at 751 days).
In contrast, patients in category 2 (curves CII) have an intermediate
TTP (264 days) and an intermediate MS (three censored; three died
at 308, 430, and 551 days, respectively; Figure 4). The patients in the
third category (curves CIII) presented with the shortest TTP (92 days)
and the shortest MS (one censored; two died at 149 and 163 days,
respectively; Figure 4). The Kaplan-Meier survival curves display a sig-
nificant difference between the three categories defined by the telomere
analyses (Figure 4; P = .0393). The TTP analyses also show significant
differences between the three categories of patients (P = .0167). Inter-
estingly, survival did not correlate with the proliferation index (P = .90)
or with the KPS scale (P = .86; Table 1) in this study.
To our knowledge, this study describes the first molecular marker that
enables such a distinction in GBM patients. Using this methodology al-
lowed the production of Kaplan-Meier survival curves that reflected the
telomere-based categorization of these patients. The three-dimensional
telomeric signature-based survival curves display significant differences
between the three categories defined by the telomere analyses.
Telomeres and Cell Cycle Distribution
We studied the genomic stability of the cells in each patient by deter-
mining the a/c ratio and the nuclear volume. The nuclear space occu-
pied by telomeres is measured by two main axes, a and b, that are equal
in length, and a third axis, c, that has a different length [26]. The dis-
tribution of telomeres in the three-dimensional space of the nucleus
varies with cell cycle; as the specific stages of the cell cycle (G0/G1, S,
and G2) phases have characteristic a/c ratios, the investigator can deter-
mine where they reside in the cell cycle [26]. The a/c ratio is a mean of
defining progression through cell cycle in interphase cells. Thus, using
this tool, we determined whether there was a difference in cell cycle
between our patient groups. We did not find significant differences
for the a/c ratio (P = .82) and for nuclear volume (P = .9244) among
the three categories. The nonsignificant differences in a/c ratios are
consistent with the high levels of proliferation in GBM and are con-
sistent with the Ki-67 staining (Table 1). Moreover, we found several
Table 1. Clinical Data of the Population Cohort.
Patient Category* Age (years) Sex First Symptoms Treatment TTP (days) MS (days) Proliferative Index (%) KPS Index
P1 3 25 M Headache Craniotomy, STUPP, Temodal 26 163 15 70
N + Vo
Seizure
P2 2 26 M Seizure Craniotomy, STUPP 301 Alive 10 90
P3 2 51 M Seizure Craniotomy, STUPP, Temodal 386 551 50 90
P4 2 55 M Headache Craniotomy, STUPP, Temodal, intra-arterial chemotherapy, CCNU 149 308 ND 40
Seizure
P5 3 58 M Left hemiparesis Craniotomy, STUPP, Temodal, intra-arterial chemotherapy 91 490 20 80
Seizure
P6 1 56 M Dysphasia Craniotomy, STUPP, Temodal 595 Alive 30 80
Headache
P7 1 24 F Headache Craniotomy, intra-arterial chemotherapy, Temodal 587 751 30 80
Right hemiparesis
P8 3 46 M Dizziness Craniotomy, STUPP, CCNU 100 880 15 70
Headache
N + Vo
P9 2 56 M Headache Craniotomy, STUPP, Temodal, intra-arterial chemotherapy, CCNU 227 Alive 12 50
Left hemiparesis
P10 2 66 F Dysphasia Craniotomy, STUPP, Temodal, intra-arterial chemotherapy 190 430 20 90
Seizures
P11 2 49 F Memory disturbances Craniotomy, STUPP, Temodal 409 Alive 30 50
Headache
Syncope
CCNU indicates lomustine; CT, computed tomography; MRI, magnetic resonance imaging; N + Vo, nausea and vomiting; ND, not determined; STUPP, temozolomide and radiotherapy.
*Three-dimensional telomere–defined categories.
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nuclear bridges indicative of breakage bridge fusion cycles in many of
these samples (Figure 5) consistent with a high degree of genomic in-
stability and telomere dysfunction.
Discussion
GBM is a devastating disease, with only minor treatment breakthroughs
in the last decades. We possess only a limited understanding of the dis-
ease process, as exemplified by the fact that patients whose conditions
were diagnosed with common histopathologic criteria display an ex-
tremely heterogeneous clinical evolution and response to treatment.
Molecular characterization has failed so far in providing a stratifica-
tion rationale. The only distinctive factors with some prognostic value
so far have been the age at diagnosis and the KPS at presentation. Pro-
liferative indices have been used with limited success to provide a
pathological tool to refine biological stratification; however, a reliable
biological and prognostic marker for GBM patients is clearly lacking.
Our previous data showed altered three-dimensional telomeric orga-
nization in plasmacytoma [20,28], cervical cancer [27,29], Burkitt lym-
phoma [18], and head and neck cancer [18].More recently, we were able
to gain a mechanistic understanding of the transition of mononuclear
Hodgkin cells to multinuclear Reed-Sternberg cells [30]. Encouraged
Figure 1. Two-dimensional (A, C, E) and three-dimensional images (B, D, F) of human GBM nuclei (blue) and their telomeres (red) imaged
and visualizedwithAxioVision4.6.Nuclear telomeredistributionpatternsdefineTAs indicatedwith anarrow in the threecategoriesof patient:
(A, B) from P7 in category 1, (C, D) from P9 in category 2, and (E, F) from P1 in category 3. The arrows point to the telomere aggregates.
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Figure 2. Number of telomeres versus relative intensities of fluorescent signal analyzed by TeloView. Lines and arrows define the three cate-
gories of cells. (A) Category 1, P7. (B) Category 2, P9. (C) Category 3, P1. P = .0275.
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Figure 3. Screenshots of human GBM nuclei (blue) and telomeres (red) with ScanView 6.0. Upper panel: Screenshot of a selected field of
the gallery of 20 scanned cells. Bottom panel: The corresponding histogram showing the distribution of classified defined cells based on the
number of telomeres/cell. (A) Category 1, P7. (B) Category 2, P9. (C) Category 3, P1. For patient details, see Table 1.
Figure 4. Kaplan-Meier curves depicting the TTP and overall survival of the three categories of population defined by telomere organization.
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by these data, we investigated whether three-dimensional nuclear telo-
meric architecture could predict disease aggressiveness inGBMand thus
provide a new basis for defining clinically relevant prognostic patient
categories. To this end, three-dimensional FISH analyses of telomeres
were carried out in a blind fashion on touch preparations of fresh
GBM samples (Table 1). We examined three-dimensional nuclear telo-
meric parameters that included the total number of telomeres, their nu-
clear distribution, and the presence of TAs (Figure 1).
Telomere numbers and their nuclear distribution differed markedly
among patients within our GBM cohort (Figures 2 and 3). Two three-
dimensional quantitative telomere analysis tools allowed for this con-
clusion. We first used TeloView, a quantitative program that measures
telomeres within the three-dimensional nuclear space in an interactive
manner [26]. TeloView analysis of the sample slides was followed by
the use of a novel tool we developed, three-dimensional TeloScan. This
imaging program allows for automated and high-throughput three-
dimensional telomere scanning and analysis and automatically displays
telomere numbers, intensities, and aggregates. Both methods led to
the same basic conclusions. On the basis of defined telomere parame-
ters, we identified three patient categories (1-3) within ourGBMpatient
cohort (Table 1; Figures 2 and 3).
Decoding of the samples allowed us to compare the clinical data with
the three-dimensional telomere signature–based patient categories. The
three categories corresponded to patients with long-term, intermediate,
and short-term survival respectively (P = .0393; Table 1 and Figure 4).
The TTP analyses showed significant differences between the three
categories of patients as well (P = .0167; Table 1 and Figure 4). There
was thus an expected correlation between TTP and MS. In this study,
the natural history of GBM evolution was therefore predicted by nu-
clear telomere architecture distinguishing long-term survivalGBM (cate-
gory 1) from short-term survival GBM (category 3). This prognostic
value of the three-dimensional nuclear telomere architecture analysis
will need to be validated with a larger set of patients. However, if
this observation is confirmed, this methodology could eventually pro-
vide valuable guidance in clinical treatment decisions by identifying
and monitoring patient responses to existing and newly emerging
therapies. The three-dimensional nuclear telomere architecture char-
acterization in GBM could be used as an individual GBM patient
biomedical profile index in tailored therapy approaches acting as an
important novel predictive biomarker. This is the case in PML-RARA
translocation in promyelocytic leukemia, which responds to all-trans
retinoic acid, and BCR-ABL translocation in chronic myelocytic leu-
kemia, which responds to imatinib mesylate [31]. Finally, we suggest
that three-dimensional nuclear telomere architecture could measure
the near-term treatment effects of a drug on the GBM tumor cells di-
rectly as a pharmacodynamic biomarker. This could be performed by
an initial three-dimensional FISH on a touch preparation slide of the
tumor on surgery to categorize the GBM patient. Three-dimensional
FISH could then be repeated during a follow-up on touch preparation
slide derived from stereotactic biopsies after a given treatment. This
stepwise analysis could allow recategorizing a patient and monitoring
the evolution of his tumor. The remodeling of the nuclear telomere
architecture and the consequent change of category of the GBM pa-
tient could then aid to adjust therapeutic options. Because the telo-
mere aggregates represent a clear distinction between normal and
tumor cells, we hypothesize that fewer TAs in the tumor would reflect
tumor response to treatment. The newly established high-throughput
semiautomatic nuclear scanning method (TeloScan) allows categoriz-
ing GBM patients in 9 to 12 hours after surgery or stereotactic biopsy.
Therefore, the telomere biomarker can be used with different clinical
surrogates and could eventually be incorporated in clinical trials as a
monitoring tool providing a new basis for more effective therapies
aimed at improving the dire prognosis of GBM.
Clinical management of patients bearing GBM is greatly influenced
by the KPS scale. In our study, the three-dimensional telomeric stratifi-
cation signature was infinitely more reliable than the KPS, themost use-
ful current clinical prognostic factor, in predictingMS and TTP. Cohort
MS in this series failed to correlate with either KPS (P = .86) or prolif-
eration index (P = .90), which is clear evidence of the usefulness of our
methods of analysis. Some studies have pointed to the value of the pro-
liferative index as a prognostic tool [32,33], but this remains highly
controversial [34].
The proliferation index measured by Ki-67 staining was confirmed
by the a/c ratio as measured with TeloView [26]. The a/c ratio defines
cell cycle progression in interphase cells and is based on the dynamic
organization of the telomeres in the three-dimensional space of the in-
terphase nucleus during the cell cycle [26]. We did not find significant
differences between the three patient categories for the a/c ratio (P = .82)
or the nuclear volume (P = .92). Specific features of three-dimensional
telomeric signatures, such as telomere numbers/nucleus, telomere
Figure 5. (A) Human GBM nuclei presenting breakage bridge fusion
(BBF), with their telomere distribution. Arrows point to nuclear
bridges indicative of breakage bridge fusion cycles. (B) Human
GBM nuclei presenting nuclear fusion. These data are observed in
all three patient categories. A qualitative evaluation showed that
these characteristic figures of GBM are most prominent in category
3, followed by category 2 and category 1.
190 Telomere Signatures in Glioblastoma Gadji et al. Neoplasia Vol. 12, No. 2, 2010
length, and number of TAs, are, as mentioned previously, causal factors
in genomic instability in cancer cells. Importantly, many of the patient
samples from all three categories displayed multiple nuclear bridges in-
dicative of breakage bridge fusion cycles, which is consistent with a high
degree of genomic instability in GBM (Figure 5). The highest incidence
of multiple nuclear fusions and breakage bridge fusions was evident in
GBM of category 3, thus supporting the notion that this new method-
ology is predictive of genomic instability and that this genomic insta-
bility directly correlates with survival.
Conclusions
Malignant GBMs have a dire prognosis. We describe for the first
time the three-dimensional nuclear telomeric architecture as a suitable
biomarker for predicting the prognosis of GBMs and linking pro-
gression to patient survival. Telomeric architecture seems to be a more
accurate parameter for monitoring GBMs than any of those in current
common use for their clinical stratification. The identification of three-
dimensional telomeric signatures for clinical categorization, combined
with our new high-throughput method for monitoring these signatures,
opens the door to future routine use of this marker as a tool for the clini-
cal management of gliomas. This marker needs to be validated with a
more extensive set of GBM patients, as well as with WHO grade 2
and grade 3 astrocytomas, to allow for a differential comparison across
the whole spectrum of astrocytic malignancy. Our findings provide a
new analysis tool, with results from 9 to 12 hours after surgery, and
add important information to the molecular mechanisms on the evolu-
tion and progression of GBMs.
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